Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 379 across all filing types
Latest filing 2025-01-31 Declaration of Voting R…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Immunovia AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short press release (1867 characters) dated January 31, 2025, titled "Ändring av antalet aktier och röster i Immunovia AB (publ)" (Change in the number of shares and votes in Immunovia AB (publ)). The core content explicitly states that the number of registered shares and votes has increased due to the exercise of warrants (teckningsoptioner serie TO 2), resulting in a new total share count. This directly relates to a change in the company's capital structure or share count. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements detailing changes in the total number of outstanding shares, even if triggered by warrant exercises. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a report announcement (RPA) as it contains the substantive information itself.
2025-01-31 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for an entity (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in Immunovia AB (publ). It specifies the number of shares held before and after a transaction, the reason for flagging ('Aktielån' - Stock loan), and the resulting ownership percentage (9.74046%). This structure, focusing on insider/major shareholder transactions and reporting changes in ownership thresholds, directly corresponds to the definition of Director's Dealing or Major Shareholding Notification. Since the document explicitly reports a change in ownership crossing a threshold (10%) due to a stock loan, it fits the criteria for Major Shareholding Notification (MRQ) or Director's Dealing (DIRS). Given the focus on the resulting percentage ownership and the crossing of a threshold, MRQ is a strong candidate, but DIRS often covers executive/director transactions, while MRQ covers significant ownership changes by any party. The content is a formal notification of a change in significant share ownership, which aligns best with Major Shareholding Notification (MRQ). It is not an earnings release, annual report, or proxy statement.
2025-01-22 Swedish
Immunovia AB announces outcome of exercise of warrants series TO 2
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the outcome of a warrant exercise program (Warrant series TO 2). It details the number of warrants exercised, the resulting capital raised (approximately 42.4 MSEK), and the resulting increase in the number of shares outstanding (dilution). This activity directly relates to changes in the company's capital structure and fundraising efforts. This fits the definition of 'Capital/Financing Update' (CAP) better than other options. It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific corporate finance event.
2025-01-20 English
Immunovia AB meddelar utfall för nyttjandet av teckningsoptioner serie TO 2
Capital/Financing Update Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the outcome of the exercise of warrants (Teckningsoptioner serie TO 2). It details the number of warrants exercised, the resulting capital raised (approx. 42.4 MSEK), and the resulting increase in the number of shares. This is a corporate action announcement related to capital structure and financing activities, specifically the conversion of options into shares, which results in new capital inflow. This aligns best with the 'Capital/Financing Update' category (CAP). Although it involves shares, it is not a general share issue announcement (SHA) but a specific financing event outcome. It is too detailed to be a simple Regulatory Filing (RNS) and is not a standard financial report (10-K, IR, ER).
2025-01-20 Swedish
Immunovia AB (Publ) presenterar valberedningen
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of the company's nomination committee (valberedning) for the upcoming 2025 Annual General Meeting. It details the members of the committee and their role in preparing proposals for the board and auditors. This type of corporate governance announcement regarding board-related committees falls under the 'Regulatory Filings' category as it is a standard corporate disclosure that does not fit into specific categories like 'Board/Management Information' (which usually refers to changes in personnel) or 'Proxy Solicitation' (which is the formal meeting notice).
2025-01-08 Swedish
Immunovia AB (Publ) presents Nomination Committee
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a Nomination Committee for the upcoming 2025 Annual General Meeting. It details the members of the committee and their purpose, which is to prepare proposals for the board and auditors. Since this is a corporate governance announcement regarding board composition and committee formation, and does not fit into specific financial reporting categories like 10-K or ER, it is best classified as a general regulatory filing or governance-related announcement. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for this type of corporate announcement.
2025-01-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.